RSS Feeds
Interferon-α for the Hypereosinophilic Syndrome
- Robert M. Zielinski, MD; and
- William D. Lawrence, MD
Excerpt
The hypereosinophilic syndrome is defined by unexplained eosinophilia (eosinophil count > 1.5 x 109/L) lasting more than 6 months (1). Characteristic clinical features include congestive heart failure with endocardial fibrosis (2), venous and arterial thromboembolism, neuropsychiatric dysfunction (3), anemia, and thrombocytopenia. These disease manifestations have been attributed to tissue infiltration by eosinophils and the direct toxic effects of the products of eosinophilic granules (1, 2, 4).
Therapy has been directed at lowering the absolute eosinophil count to below 1 x 109/L with prednisone and the cytotoxic agent, hydroxyurea (1, 5). This therapeutic approach appears to have dramatically improved median survival
This 100-word excerpt has been provided in the absence of an abstract.
Article and Author Information
-
From the Veterans Affairs Medical Center and the State University of New York at Buffalo, Buffalo, New York. For current author addresses, see end of text.
-
Requests for Reprints: William D. Lawrence, MD, Century Medical Associates, 1616 Kensington Avenue, Buffalo, NY 14215.
-
Current Author Addresses: Dr. Zielinski: Department of Medicine, Buffalo Veterans Affairs Medical Center, 3495 Bailey Avenue, Buffalo, NY 14215.
Dr. Lawrence: Century Medical Associates, 1616 Kensington Avenue, Buffalo, NY 14215.
